Your browser doesn't support javascript.
loading
AHSA1 is a promising therapeutic target for cellular proliferation and proteasome inhibitor resistance in multiple myeloma.
Gu, Chunyan; Wang, Yajun; Zhang, Lulin; Qiao, Li; Sun, Shanliang; Shao, Miaomiao; Tang, Xiaozhu; Ding, Pinggang; Tang, Chao; Cao, Yuhao; Zhou, Yanyan; Guo, Mengjie; Wei, Rongfang; Li, Nianguang; Xiao, Yibei; Duan, Jinao; Yang, Ye.
  • Gu C; Nanjing Hospital of Chinese Medicine affiliated to Nanjing University of Chinese Medicine, Nanjing, 210023, China.
  • Wang Y; School of Medicine & Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing, 210023, China.
  • Zhang L; School of Medicine & Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing, 210023, China.
  • Qiao L; School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, 210023, China.
  • Sun S; School of Medicine & Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing, 210023, China.
  • Shao M; School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, 210023, China.
  • Tang X; School of Medicine & Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing, 210023, China.
  • Ding P; School of Medicine & Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing, 210023, China.
  • Tang C; School of Medicine & Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing, 210023, China.
  • Cao Y; School of Medicine & Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing, 210023, China.
  • Zhou Y; School of Medicine & Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing, 210023, China.
  • Guo M; School of Medicine & Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing, 210023, China.
  • Wei R; School of Medicine & Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing, 210023, China.
  • Li N; School of Medicine & Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing, 210023, China.
  • Xiao Y; School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, 210023, China. linianguang@njucm.edu.cn.
  • Duan J; School of Pharmacy, China Pharmaceutical University, Nanjing, 211198, China. yibei.xiao@cpu.edu.cn.
  • Yang Y; School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, 210023, China. dja@njucm.edu.cn.
J Exp Clin Cancer Res ; 41(1): 11, 2022 Jan 06.
Article en En | MEDLINE | ID: mdl-34991674
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Bufanólidos / Chaperonas Moleculares / Perfilación de la Expresión Génica / Inhibidores de Proteasoma / Mieloma Múltiple / Antineoplásicos Límite: Animals / Humans Idioma: En Año: 2022 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Bufanólidos / Chaperonas Moleculares / Perfilación de la Expresión Génica / Inhibidores de Proteasoma / Mieloma Múltiple / Antineoplásicos Límite: Animals / Humans Idioma: En Año: 2022 Tipo del documento: Article